Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ITOSNASDAQ:JNCENASDAQ:SLDBNASDAQ:VIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITOSiTeos Therapeutics$10.00-0.2%$8.22$4.80▼$18.13$382.74M1.51675,763 shs650,936 shsJNCEJounce Therapeutics$1.88$1.89$0.58▼$5.87$98.94M0.752.46 million shs169,314 shsSLDBSolid Biosciences$4.65+0.9%$3.42$2.41▼$10.37$360.45M2.221.16 million shs1.07 million shsVIGLVigil Neuroscience$7.92+0.5%$4.54$1.31▼$7.95$369.64M3.43739,353 shs2.80 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITOSiTeos Therapeutics-0.20%0.00%+18.91%+45.14%-33.11%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%0.00%SLDBSolid Biosciences+0.87%+0.87%+60.34%-1.06%-31.62%VIGLVigil Neuroscience+0.51%+0.76%+218.07%+330.43%+104.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationITOSiTeos Therapeutics3.8104 of 5 stars4.14.00.00.02.73.30.6JNCEJounce TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASLDBSolid Biosciences3.4373 of 5 stars4.63.00.00.02.01.70.6VIGLVigil Neuroscience3.9741 of 5 stars4.05.00.00.03.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceITOSiTeos Therapeutics 2.14Hold$15.8658.57% UpsideJNCEJounce Therapeutics 0.00N/AN/AN/ASLDBSolid Biosciences 3.23Buy$14.90220.43% UpsideVIGLVigil Neuroscience 2.00Hold$10.8036.36% UpsideCurrent Analyst Ratings BreakdownLatest JNCE, ITOS, SLDB, and VIGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/6/2025SLDBSolid BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.005/28/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$13.00 ➝ $12.005/28/2025ITOSiTeos TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$10.00 ➝ $12.005/28/2025VIGLVigil NeuroscienceStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$11.00 ➝ $8.005/27/2025VIGLVigil NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$14.00 ➝ $8.005/23/2025VIGLVigil NeuroscienceMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/22/2025VIGLVigil NeuroscienceGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Neutral$8.005/22/2025VIGLVigil NeuroscienceCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform5/22/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$16.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookITOSiTeos Therapeutics$35M10.93N/AN/A$16.16 per share0.62JNCEJounce Therapeutics$82M1.21N/AN/A$3.54 per share0.53SLDBSolid Biosciences$8.09M44.55N/AN/A$3.43 per share1.36VIGLVigil NeuroscienceN/AN/AN/AN/A$1.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateITOSiTeos Therapeutics-$134.41M-$3.04N/AN/AN/AN/A-21.37%-18.55%8/6/2025 (Estimated)JNCEJounce Therapeutics-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/ASLDBSolid Biosciences-$124.70M-$2.99N/AN/AN/AN/A-68.15%-55.33%8/12/2025 (Estimated)VIGLVigil Neuroscience-$84.26M-$2.05N/AN/AN/AN/A-111.70%-74.67%8/12/2025 (Estimated)Latest JNCE, ITOS, SLDB, and VIGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SLDBSolid Biosciences-$0.53-$0.59-$0.06-$0.59N/AN/A5/7/2025Q1 2025VIGLVigil Neuroscience-$0.53-$0.49+$0.04-$0.49N/AN/A4/28/2025Q1 2025ITOSiTeos Therapeutics-$0.94-$0.80+$0.14-$0.80$9.35 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthITOSiTeos TherapeuticsN/AN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/AVIGLVigil NeuroscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioITOSiTeos TherapeuticsN/A14.1314.13JNCEJounce TherapeuticsN/A8.378.37SLDBSolid BiosciencesN/A10.8910.89VIGLVigil NeuroscienceN/A2.972.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipITOSiTeos Therapeutics97.16%JNCEJounce Therapeutics80.66%SLDBSolid Biosciences81.46%VIGLVigil Neuroscience83.64%Insider OwnershipCompanyInsider OwnershipITOSiTeos Therapeutics12.50%JNCEJounce Therapeutics6.92%SLDBSolid Biosciences1.90%VIGLVigil Neuroscience18.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableITOSiTeos Therapeutics9038.27 million33.49 millionOptionableJNCEJounce Therapeutics13752.63 million48.99 millionOptionableSLDBSolid Biosciences10077.51 million76.04 millionOptionableVIGLVigil Neuroscience4046.67 million38.27 millionNot OptionableJNCE, ITOS, SLDB, and VIGL HeadlinesRecent News About These CompaniesVigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Consensus Rating of "Hold" from AnalystsJune 17 at 3:14 AM | marketbeat.comTwo Sigma Investments LP Acquires 41,836 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)June 12, 2025 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of ShareholdersJune 9, 2025 | prnewswire.comWall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a BetJune 9, 2025 | zacks.comSquarepoint Ops LLC Acquires New Shares in Vigil Neuroscience, Inc. (NASDAQ:VIGL)June 9, 2025 | marketbeat.comMillennium Management LLC Boosts Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)June 9, 2025 | marketbeat.comJane Street Group LLC Invests $83,000 in Vigil Neuroscience, Inc. (NASDAQ:VIGL)June 9, 2025 | marketbeat.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Holdings Lifted by Two Sigma Advisers LPJune 8, 2025 | marketbeat.comVigil Neuroscience halts Phase 2 trial for ALSP treatmentJune 5, 2025 | investing.comVigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II TrialJune 5, 2025 | biospace.comVIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...June 5, 2025 | morningstar.comDisappointing results see Vigil Neuro drop iluzanebart developmentJune 4, 2025 | thepharmaletter.comVIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the FirmJune 4, 2025 | prnewswire.comVigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSPJune 4, 2025 | globenewswire.comShould You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?June 2, 2025 | zacks.comHC Wainwright Has Bearish Forecast for VIGL FY2026 EarningsMay 30, 2025 | marketbeat.comStifel cuts Vigil Neuroscience stock rating, lowers target to $8May 29, 2025 | investing.comVigil Neuroscience (NASDAQ:VIGL) Downgraded by Stifel Nicolaus to HoldMay 29, 2025 | marketbeat.comStifel Downgrades Vigil Neuroscience (VIGL)May 29, 2025 | msn.comHC Wainwright Reiterates "Neutral" Rating for Vigil Neuroscience (NASDAQ:VIGL)May 28, 2025 | marketbeat.comHC Wainwright & Co. Downgrades Vigil Neuroscience (VIGL)May 28, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsSarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesBy Leo Miller | June 18, 2025View Sarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesJNCE, ITOS, SLDB, and VIGL Company DescriptionsiTeos Therapeutics NASDAQ:ITOS$10.00 -0.02 (-0.20%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$10.01 +0.01 (+0.05%) As of 06/18/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Jounce Therapeutics NASDAQ:JNCEJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.Solid Biosciences NASDAQ:SLDB$4.65 +0.04 (+0.87%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$4.83 +0.18 (+3.87%) As of 06/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.Vigil Neuroscience NASDAQ:VIGL$7.92 +0.04 (+0.51%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$7.90 -0.01 (-0.19%) As of 06/18/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
